Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
2006 1
2008 5
2009 8
2010 14
2011 18
2012 13
2013 11
2014 20
2015 24
2016 24
2017 22
2018 17
2019 10
2020 31
2021 49
2022 26
2023 16
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

277 results

Results by year

Filters applied: . Clear all
Page 1
The immunopathology of sepsis and potential therapeutic targets.
van der Poll T, van de Veerdonk FL, Scicluna BP, Netea MG. van der Poll T, et al. Among authors: van de veerdonk fl. Nat Rev Immunol. 2017 Jul;17(7):407-420. doi: 10.1038/nri.2017.36. Epub 2017 Apr 24. Nat Rev Immunol. 2017. PMID: 28436424 Review.
Understanding COVID-19-associated coagulopathy.
Conway EM, Mackman N, Warren RQ, Wolberg AS, Mosnier LO, Campbell RA, Gralinski LE, Rondina MT, van de Veerdonk FL, Hoffmeister KM, Griffin JH, Nugent D, Moon K, Morrissey JH. Conway EM, et al. Among authors: van de veerdonk fl. Nat Rev Immunol. 2022 Oct;22(10):639-649. doi: 10.1038/s41577-022-00762-9. Epub 2022 Aug 5. Nat Rev Immunol. 2022. PMID: 35931818 Free PMC article. Review.
mTOR- and HIF-1α-mediated aerobic glycolysis as metabolic basis for trained immunity.
Cheng SC, Quintin J, Cramer RA, Shepardson KM, Saeed S, Kumar V, Giamarellos-Bourboulis EJ, Martens JH, Rao NA, Aghajanirefah A, Manjeri GR, Li Y, Ifrim DC, Arts RJ, van der Veer BM, Deen PM, Logie C, O'Neill LA, Willems P, van de Veerdonk FL, van der Meer JW, Ng A, Joosten LA, Wijmenga C, Stunnenberg HG, Xavier RJ, Netea MG. Cheng SC, et al. Among authors: van de veerdonk fl. Science. 2014 Sep 26;345(6204):1250684. doi: 10.1126/science.1250684. Science. 2014. PMID: 25258083 Free PMC article.
Aspergillus fumigatus morphology and dynamic host interactions.
van de Veerdonk FL, Gresnigt MS, Romani L, Netea MG, Latgé JP. van de Veerdonk FL, et al. Nat Rev Microbiol. 2017 Nov;15(11):661-674. doi: 10.1038/nrmicro.2017.90. Epub 2017 Sep 18. Nat Rev Microbiol. 2017. PMID: 28919635 Review.
The pathophysiology of sepsis and precision-medicine-based immunotherapy.
Giamarellos-Bourboulis EJ, Aschenbrenner AC, Bauer M, Bock C, Calandra T, Gat-Viks I, Kyriazopoulou E, Lupse M, Monneret G, Pickkers P, Schultze JL, van der Poll T, van de Veerdonk FL, Vlaar APJ, Weis S, Wiersinga WJ, Netea MG. Giamarellos-Bourboulis EJ, et al. Among authors: van de veerdonk fl. Nat Immunol. 2024 Jan;25(1):19-28. doi: 10.1038/s41590-023-01660-5. Epub 2024 Jan 2. Nat Immunol. 2024. PMID: 38168953 Review.
A guiding map for inflammation.
Netea MG, Balkwill F, Chonchol M, Cominelli F, Donath MY, Giamarellos-Bourboulis EJ, Golenbock D, Gresnigt MS, Heneka MT, Hoffman HM, Hotchkiss R, Joosten LAB, Kastner DL, Korte M, Latz E, Libby P, Mandrup-Poulsen T, Mantovani A, Mills KHG, Nowak KL, O'Neill LA, Pickkers P, van der Poll T, Ridker PM, Schalkwijk J, Schwartz DA, Siegmund B, Steer CJ, Tilg H, van der Meer JWM, van de Veerdonk FL, Dinarello CA. Netea MG, et al. Among authors: van de veerdonk fl. Nat Immunol. 2017 Jul 19;18(8):826-831. doi: 10.1038/ni.3790. Nat Immunol. 2017. PMID: 28722720 Free PMC article.
Trained immunity, tolerance, priming and differentiation: distinct immunological processes.
Divangahi M, Aaby P, Khader SA, Barreiro LB, Bekkering S, Chavakis T, van Crevel R, Curtis N, DiNardo AR, Dominguez-Andres J, Duivenvoorden R, Fanucchi S, Fayad Z, Fuchs E, Hamon M, Jeffrey KL, Khan N, Joosten LAB, Kaufmann E, Latz E, Matarese G, van der Meer JWM, Mhlanga M, Moorlag SJCFM, Mulder WJM, Naik S, Novakovic B, O'Neill L, Ochando J, Ozato K, Riksen NP, Sauerwein R, Sherwood ER, Schlitzer A, Schultze JL, Sieweke MH, Benn CS, Stunnenberg H, Sun J, van de Veerdonk FL, Weis S, Williams DL, Xavier R, Netea MG. Divangahi M, et al. Among authors: van de veerdonk fl. Nat Immunol. 2021 Jan;22(1):2-6. doi: 10.1038/s41590-020-00845-6. Nat Immunol. 2021. PMID: 33293712 Free PMC article.
Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial.
Writing Committee for the REMAP-CAP Investigators; Higgins AM, Berry LR, Lorenzi E, Murthy S, McQuilten Z, Mouncey PR, Al-Beidh F, Annane D, Arabi YM, Beane A, van Bentum-Puijk W, Bhimani Z, Bonten MJM, Bradbury CA, Brunkhorst FM, Burrell A, Buzgau A, Buxton M, Charles WN, Cove M, Detry MA, Estcourt LJ, Fagbodun EO, Fitzgerald M, Girard TD, Goligher EC, Goossens H, Haniffa R, Hills T, Horvat CM, Huang DT, Ichihara N, Lamontagne F, Marshall JC, McAuley DF, McGlothlin A, McGuinness SP, McVerry BJ, Neal MD, Nichol AD, Parke RL, Parker JC, Parry-Billings K, Peters SEC, Reyes LF, Rowan KM, Saito H, Santos MS, Saunders CT, Serpa-Neto A, Seymour CW, Shankar-Hari M, Stronach LM, Turgeon AF, Turner AM, van de Veerdonk FL, Zarychanski R, Green C, Lewis RJ, Angus DC, McArthur CJ, Berry S, Derde LPG, Gordon AC, Webb SA, Lawler PR. Writing Committee for the REMAP-CAP Investigators, et al. Among authors: van de veerdonk fl. JAMA. 2023 Jan 3;329(1):39-51. doi: 10.1001/jama.2022.23257. JAMA. 2023. PMID: 36525245 Free PMC article.
Metabolic Induction of Trained Immunity through the Mevalonate Pathway.
Bekkering S, Arts RJW, Novakovic B, Kourtzelis I, van der Heijden CDCC, Li Y, Popa CD, Ter Horst R, van Tuijl J, Netea-Maier RT, van de Veerdonk FL, Chavakis T, Joosten LAB, van der Meer JWM, Stunnenberg H, Riksen NP, Netea MG. Bekkering S, et al. Among authors: van de veerdonk fl. Cell. 2018 Jan 11;172(1-2):135-146.e9. doi: 10.1016/j.cell.2017.11.025. Cell. 2018. PMID: 29328908 Free article.
Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19.
REMAP-CAP Investigators; Gordon AC, Mouncey PR, Al-Beidh F, Rowan KM, Nichol AD, Arabi YM, Annane D, Beane A, van Bentum-Puijk W, Berry LR, Bhimani Z, Bonten MJM, Bradbury CA, Brunkhorst FM, Buzgau A, Cheng AC, Detry MA, Duffy EJ, Estcourt LJ, Fitzgerald M, Goossens H, Haniffa R, Higgins AM, Hills TE, Horvat CM, Lamontagne F, Lawler PR, Leavis HL, Linstrum KM, Litton E, Lorenzi E, Marshall JC, Mayr FB, McAuley DF, McGlothlin A, McGuinness SP, McVerry BJ, Montgomery SK, Morpeth SC, Murthy S, Orr K, Parke RL, Parker JC, Patanwala AE, Pettilä V, Rademaker E, Santos MS, Saunders CT, Seymour CW, Shankar-Hari M, Sligl WI, Turgeon AF, Turner AM, van de Veerdonk FL, Zarychanski R, Green C, Lewis RJ, Angus DC, McArthur CJ, Berry S, Webb SA, Derde LPG. REMAP-CAP Investigators, et al. Among authors: van de veerdonk fl. N Engl J Med. 2021 Apr 22;384(16):1491-1502. doi: 10.1056/NEJMoa2100433. Epub 2021 Feb 25. N Engl J Med. 2021. PMID: 33631065 Free PMC article. Clinical Trial.
277 results